Pharmacologic inhibition of PARP5, but not that of PARP1 or 2, promotes cytokine production and osteoclastogenesis through different pathways.

Yosuke Asano,Yoshinori Matsumoto,Fang He,Takayuki Katsuyama, Eri Katsuyama,Shigetomo Tsuji,Hiroshi Kamioka,Jose La Rose,Robert Rottapel,Jun Wada

Clinical and experimental rheumatology（2023）

引用 2|浏览13

暂无评分

摘要

Our results show that pharmacologic inhibition of PARP5 against cancers unexpectedly induces adverse autoinflammatory side effects through activation of innate immunity, unlike inhibition of other PARPs.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要